Congress Scientific Watch

From the 65th American Society of Hematology Annual Meeting:
Switching from brentuximab vedotin to nivolumab alongside chemotherapy increased progression-free survival and reduced toxicity in patients aged 60 years and older with classic Hodgkin’s lymphoma

Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.

Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.

Create a new account

Not yet an ESMO Member? Find out more about the benefits offered to ESMO Member s.

If you have been an ESMO Member or have attended an ESMO event in the past, you already have an ESMO account and there is no need to create another.

Create My ESMO account

I have an ESMO account

Create a new account